Patrick Durez

Summary

Country: Belgium

Publications

  1. ncbi Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone
    Patrick Durez
    Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate 10, Brussels, Belgium
    Arthritis Rheum 56:3919-27. 2007
  2. ncbi Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    Paul Emery
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds Teaching Hospitals Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom, UK
    Lancet 372:375-82. 2008
  3. ncbi Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study
    Rieke Alten
    Department of Internal Medicine II, Schlosspark Klinik Teaching Hospital of the Charité, University Medicine Berlin, Heubnerweg, Berlin 14059, Germany
    BMC Musculoskelet Disord 12:153. 2011
  4. ncbi Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
    Bert Vander Cruyssen
    Arthritis Res Ther 8:406. 2006
  5. ncbi Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis
    Patrick Durez
    Department of Rheumatology, Cliniques Universitaires St Luc, Universite Catholique de Louvain, 10, B 1200 Bruxelles, Belgium
    Ann Rheum Dis 66:1098-105. 2007
  6. ncbi Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, B 9000 Gent, Belgium
    Arthritis Res Ther 8:R112. 2006
  7. ncbi Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Arthritis Res Ther 12:R77. 2010
  8. ncbi Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis
    Valérie Badot
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Arthritis Res Ther 11:R57. 2009
  9. ncbi DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, Belgium
    Arthritis Res Ther 7:R1063-71. 2005
  10. ncbi Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patients
    Charles Sèbiyo Batcho
    Universite Catholique de Louvain, Brussels, Belgium
    Arthritis Care Res (Hoboken) 63:135-41. 2011

Collaborators

Detail Information

Publications18

  1. ncbi Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone
    Patrick Durez
    Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate 10, Brussels, Belgium
    Arthritis Rheum 56:3919-27. 2007
    ....
  2. ncbi Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    Paul Emery
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds Teaching Hospitals Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom, UK
    Lancet 372:375-82. 2008
    ....
  3. ncbi Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study
    Rieke Alten
    Department of Internal Medicine II, Schlosspark Klinik Teaching Hospital of the Charité, University Medicine Berlin, Heubnerweg, Berlin 14059, Germany
    BMC Musculoskelet Disord 12:153. 2011
    ....
  4. ncbi Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
    Bert Vander Cruyssen
    Arthritis Res Ther 8:406. 2006
  5. ncbi Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis
    Patrick Durez
    Department of Rheumatology, Cliniques Universitaires St Luc, Universite Catholique de Louvain, 10, B 1200 Bruxelles, Belgium
    Ann Rheum Dis 66:1098-105. 2007
    ..A measure of manual ability was developed, through the Rasch measurement model, by adapting and validating the ABILHAND questionnaire, which measures the patient's perceived difficulty in performing everyday manual activities...
  6. ncbi Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, B 9000 Gent, Belgium
    Arthritis Res Ther 8:R112. 2006
    ..Disease activity measured by the DAS28 at week 14 or 22 of infliximab therapy was the best predictor of long-term attrition...
  7. ncbi Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Arthritis Res Ther 12:R77. 2010
    ..The objectives of this study were to evaluate the continuation rate of infliximab and its clinical effect over a 7-year period and to document the reasons for discontinuation...
  8. ncbi Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis
    Valérie Badot
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Arthritis Res Ther 11:R57. 2009
    ....
  9. ncbi DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, Belgium
    Arthritis Res Ther 7:R1063-71. 2005
    ..We proved that the momentary DAS28 score correlates best with this decision and demonstrated the robustness of the score and the coefficients of the DAS28 in a cohort of RA patients under infliximab therapy...
  10. ncbi Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patients
    Charles Sèbiyo Batcho
    Universite Catholique de Louvain, Brussels, Belgium
    Arthritis Care Res (Hoboken) 63:135-41. 2011
    ..ABILHAND is a Rasch-built questionnaire that measures manual ability in rheumatoid arthritis (RA) patients. This study aimed to examine the test-retest reliability and the responsiveness of ABILHAND in RA patients...
  11. ncbi The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
    Bert Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Arthritis Res Ther 12:R169. 2010
    ....
  12. ncbi Listeria infections associated with infliximab: case reports
    Thomas Kesteman
    Microbiology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, MBLG 54 92, Avenue Hippocrate, 54, 1200, Brussels, Belgium
    Clin Rheumatol 26:2173-5. 2007
    ..They enhance the likelihood for this drug to increase the risk for infections with germs like Listeria...
  13. ncbi Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Arthritis Rheum 58:964-75. 2008
    ..To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX)...
  14. ncbi A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis
    Rene Westhovens
    J Rheumatol 33:847-53. 2006
    ....
  15. ncbi Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis
    Federico Díaz González
    Service of Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canary Islands, Spain
    Ann Rheum Dis 66:628-32. 2007
    ..Several clinical and experimental lines of evidence suggest that leucotriene B4 (LTB4), an arachidonic acid derivative with potent proinflammatory properties, plays a key role in the pathophysiology of rheumatoid arthritis (RA)...
  16. ncbi Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    J Rheumatol 33:2162-6. 2006
    ..To determine the mechanism of action of abatacept, we analyzed changes in the serum levels of inflammatory biomarkers in the patients enrolled in this trial...
  17. ncbi Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    Arthritis Rheum 52:2263-71. 2005
    ..To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA-4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy...
  18. ncbi Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR
    John A Snowden
    Department of Rheumatology, Felix-Platter-Spital, University of Basel, Basel, Switzerland
    J Rheumatol 31:482-8. 2004
    ..Clinical trials are necessary to develop this approach in patients with aggressive disease who have failed conventional treatment including anti-tumor necrosis factor agents...